30 results about "Swine plague" patented technology

This invention belongs to the field of molecular marker technology, specifically relating to SNP molecular markers, primers, and applications of the PRRX2 gene associated with African swine fever virus (ASFV) antibody levels. The SNP molecular marker is located at 143 bp of exon 3 of the porcine PRRX2 gene (genotype XM_005654574.2), exhibiting T / C polymorphism. The nucleotide sequence of the SNP molecular marker is shown in SEQ ID NO.3. The molecular marker provided by this invention is closely associated with ASFV antibody levels in pigs. Compared to pigs with the TC / CC genotype at this locus, pigs with the TT genotype have higher ASFV antibody levels in their serum. This molecular marker can be applied to breed high-quality breeding pigs resistant to ASFV, thereby effectively improving the economic benefits of pig farming.

The invention belongs to the field of biology, and discloses a coating protein for diagnosis of an African swine fever virus antibody, application and a kit, and the coating protein comprises a p22 protein and an E199L protein; the amino acid sequence of the p22 protein is as shown in SEQ ID NO: 1, and the amino acid sequence of the E199L protein is as shown in SEQ ID NO: 3. The coating protein is composed of recombinant proteins of p22 and E199L, the two recombinant proteins can react with ASF positive serum and have good reactogenicity, and the detection kit based on the coating protein is high in detection precision, strong in specificity and good in repeatability.

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

The invention relates to the technical field of prevention and treatment of porcine envelope virus infection, in particular to a pomegranate peel extract as well as a preparation method and application thereof, a composition for preventing and treating porcine envelope virus infection comprises the pomegranate peel extract, and porcine envelope virus comprises at least one of porcine epidemic diarrhea virus and African swine fever virus. The pharmaceutical composition has the effects of being good in prevention and treatment effect on diseases caused by PEDV and ASFV, high in safety and free of toxic and side effects.

The invention provides a kit for detecting African swine fever viruses and a triple digital PCR detection method, the African swine fever viruses comprise ASFV I + R type strains, ASFV II type strains and ASFV recombinant strains, and the kit comprises a forward primer, a reverse primer and a probe for detecting the African swine fever viruses; the sequences of a forward primer and a reverse primer of the ASFV I + R type strain are respectively as shown in SEQ ID NO.1 and SEQ ID NO.2, and the sequence of the probe is as shown in SEQ ID NO.3; the sequences of a forward primer and a reverse primer of the ASFV II type strain are respectively as shown in SEQ ID NO.4 and SEQ ID NO.5, and the sequence of the probe is as shown in SEQ ID NO.6; the sequences of a forward primer and a reverse primer of the ASFV recombinant strain are respectively shown as SEQ ID NO.7 and SEQ ID NO.8, and the sequence of the probe is shown as SEQ ID NO.9. The triple digital PCR detection method provided by the invention can accurately identify the ASFV type I, the ASFV type II and the recombinant strains, has no cross reaction with PCV2, PRV, PRRSV, PEDV, PDCoV and other common swine disease pathogens, and provides a high-sensitivity and high-accuracy detection means for rapid identification of the ASFV type I, the ASFV type II and the recombinant strains.

This invention belongs to the field of biotechnology, specifically relating to a strain of Bacillus licheniformis, an antibacterial agent, a method for preparing antibacterial active substances, and their applications. The Bacillus licheniformis DCGGN-121 provided by this invention has the preservation number CCTCC NO: M 2024878. The bacteriocins prepared from this strain are effective against African swine fever virus (ASFV), Seneca virus (SVA), and enterovirus 71 (EV71). The results of the examples show that the bacteriocins prepared from Bacillus licheniformis DCGGN-121 can significantly reduce the replication levels of ASFV, SVA, and EV71, as well as reduce the expression of ASFV-p72, SVA-VP2, and EV71-VP1 proteins. Bacillus licheniformis DCGGN-121 can be used to prepare natural microecological preparations, suitable for livestock farming.

Compounds that modulate the function, activity and / or expression of porcine leukocyte antigen complex II (SLA II) genes and / or SLA II proteins, use for medicine, use as medicaments or use for the treatment or prevention of ASF or ASFV infection are disclosed. The present disclosure also provides the use of the SLA-DMA, SLA-DMB, RFXANK, RFXAP5, and CIITA genes to achieve ASFV resistance.

The utility model provides a kind of enzyme label plate cleaning device for hog cholera virus detection, it is related to the field of cleaning technology, including workbench, the upper surface of workbench is equipped with two support columns, the outer surface of each support column is equipped with electric slide rail A, the outer surface of each electric slide rail A is slidably installed with sliding block A, the outer surface of two sliding blocks A is commonly equipped with electric slide rail B, the outer surface of electric slide rail B is slidably installed with sliding block B, the outer surface of sliding block B is equipped with shunt block, the bottom of shunt block is equipped with multiple cleaning spray heads;The utility model is equipped with electric slide rail A and electric slide rail B cooperation sliding block A sliding block B, realize the flexible movement of cleaning spray head in vertical and horizontal space, can accurately cover each hole site of enzyme label plate, avoid the problem that traditional fixed cleaning needs manual adjustment, ensure the consistency of enzyme label plate cleaning effect, significantly improve detection efficiency.

The application provides a preparation method and product of a full synthetic fiber F9 grade air filter material, and the preparation method comprises the following steps: a. taking raw materials of synthetic fibers and ultrafine fibers according to weight ratios, adding water into the mixed raw materials, mixing, and stirring and dispersing into a slurry; b. preparing a filter material from the slurry according to an existing wet forming method; c. after the filter material is dehydrated, acrylic resin liquid is coated on the surface of the filter material; and d. the filter material coated with the acrylic resin liquid is sequentially passed through three groups of drying cylinders, so that the water content of the dried filter material is less than 5%. The application provides a new type of filter material for filtering and isolating bacteria in air, and effectively solves the problem of African swine fever.

The invention provides the antibody specifically bound with the African swine fever virus CD2v protein and the application thereof, the antibody is high in titer and stable in property, can be bound with ASFV infected cells, and provides an important tool for ASFV detection, CD2v antigen or fragment detection and CD2v protein structure analysis.

The invention relates to the technical field of biology. The invention provides an African swine fever virus sample protection solution, which is characterized by comprising the following components in percentage by weight: 15 to 35 percent of guanidine isothiocyanate, 0.4 to 2.0 percent of sodium dodecyl sarcosinate, 0.8 to 3.0 percent of Ectoine, 0.1 to 0.5 percent of tris (2-carboxyethyl) phosphine hydrochloride, 0.2 to 0.8 percent of disodium ethylene diamine tetraacetate, 0.4 to 1.5 percent of sodium citrate and the balance of Tris-HCl buffer solution. The protection liquid can thoroughly inactivate viruses to guarantee safety, can resist high temperature, and effectively solves the problem of preservation of African swine fever samples at high temperature; meanwhile, the detection sensitivity of a sample treated by the protection liquid is better, and the accuracy is higher.

The invention relates to the technical field of porcine envelop virus infection prevention and treatment, in particular to application of hydroxytyrosol in preparation of drugs or feed additives for preventing and treating porcine envelop virus infection.The porcine envelop virus comprises at least one of porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus and African swine fever virus. The medicine or feed additive for preventing and treating swine envelope virus infection comprises hydroxytyrosol and auxiliary materials. The application has the effects of remarkably inhibiting envelope virus replication, reducing toxicity, overcoming the defects of vaccine immune failure, virus variation induced by antiviral drugs and the like, effectively reducing the morbidity and mortality of piglets, and being high in safety and free of toxic and side effects.

This invention belongs to the field of foot-and-mouth disease (FMD) treatment technology, specifically relating to a novel use of the compound CDDO-Im for the prevention or treatment of FMD. This invention unexpectedly discovered that the compound CDDO-Im can induce the expression of FMD virus structural proteins VP0, VP3, and VP1, inhibit FMD virus replication, and thus inhibit FMD virus infection. Furthermore, the compound CDDO-Im has no effect on African swine fever virus replication and can specifically inhibit FMD virus, making it suitable for preparing drugs or adjuvants against FMD virus infection to inhibit FMD virus replication.

Provided herein are methods for inactivating an attenuated pathogen comprising contacting a microorganism with UV light in the presence of riboflavin such that the integrity of the antigen protein of the pathogen is maintained. In some embodiments, the viral pathogen is African swine fever virus (ASFV). Vaccine compositions comprising attenuated pathogens and methods of use thereof are also provided.

The invention provides the antibody specifically bound with the African swine fever virus CD2v protein and the application thereof, the antibody is high in titer and stable in property, can be bound with ASFV infected cells, and provides an important tool for ASFV detection, CD2v antigen or fragment detection and CD2v protein structure analysis.

A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and / or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and / or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

The present invention belongs to the technical field of antiviral drugs. Provided is the use of thalicarpine in the preparation of an antiviral drug. The present invention demonstrates at the cellular level that thalicarpine has an inhibitory effect on a variety of viruses causing common infectious diseases in domestic pigs, especially having a significant inhibitory effect on the proliferation of African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2) and porcine epidemic diarrhea virus (PEDV) in vitro. Further disclosed in the present invention are an antiviral composition composed of an active ingredient, i.e. thalicarpine, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient, and the use of the composition in the preparation of a viral infection inhibitor and / or in the preparation of a pharmaceutical preparation for preventing and / or treating a viral infectious disease, thereby providing a basis for the development of a new broad-spectrum antiviral drug.

The present invention relates to the expression of a CHO cell against the ASFVD 117L encoded protein, the preparation of monoclonal antibodies, epitope identification and application. By constructing a eukaryotic expression vector pCDNA3.4-D117L-strep, transiently transfecting CHO cells to express recombinant p17 protein, immunizing Balb / c mice after purification, fusing the spleen cells of mice with myeloma SP2 / 0 cells to prepare hybridoma cells after four immunizations, and then using the indirect ELISA method for subcloning to obtain monoclonal antibodies against p17 protein, and identifying the antigen epitope corresponding to the antibody as <supgt;8< / supgt;LLSHNLSTREGIK<supgt;20< / supgt>.

The present invention relates to the use of compositions containing an effective amount of peroxyacid to reduce the viral load in animal feed and water supply, as well as the surfaces and containers in which the feed and water come into contact. Another aspect of the present invention relates to a formaldehyde-free antiviral composition suitable for animal feed, water, and associated storage containers, wherein the composition is capable of controlling the growth of viruses, including but not limited to African Swine Fever, PED, and Avian Influenza. Another aspect of the present invention relates to a kit for treating animal feed to control the growth of viruses comprising a peroxypropionic acid concentrate and a buffered solution.

Disclosed herein are recombinant antibodies or the fragments comprising a light chain variable (VL) domain and a heavy chain variable (VH domain) thereof for detecting African swine fever virus (ASFV). Also disclosed herein are kits comprising the recombinant antibodies, and methods of diagnosing the infection of ASFV by using the recombinant antibody or kit.

The application discloses application of phloretin in preparation of a medicine or a feed additive for treating or preventing porcine capsid virus infection, the medicine being phloretin or oral liquid, granules, tablets, powder prepared by adding a solvent or excipient with phloretin as an effective component, and a dosage being 2.5-10 mg / kg of pig body weight; or the phloretin being directly added into feed, and an adding amount being 0.01%-0.03% of the total weight of pig feed. The application takes phloretin or a composition containing phloretin as the medicine or the feed additive, is high in safety, free of toxic side effects, has a significant effect of inhibiting replication of capsid viruses such as porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus and African swine fever virus, reducing the virulence of porcine capsid virus, overcoming the disadvantages of possible immunization failure of vaccination and virus variation caused by use of antiviral drugs, effectively reducing the morbidity and mortality of piglets infected with porcine capsid virus, and having the effect of preventing and treating or preventing porcine capsid virus infection diseases.

The invention relates to the technical field of virus detection, and particularly discloses an African swine fever virus fluorescent PCR detection kit. The kit comprises three groups of specific primer probes, namely a B646L gene primer probe, an EP402R gene primer probe and an endogenous reference gene primer probe, the detection method of the kit comprises the following steps: adding a sample to be detected into the integrated detection reagent card, adsorbing nucleic acid by the magnetic beads, and amplifying the nucleic acid. By designing the specific primers and probes and optimizing the reaction system and conditions, the B646L gene and the EP402R gene can be simultaneously detected in one reaction, and the amplification reactions of the two genes do not interfere with each other, so that the prepared fluorescent PCR detection kit for the African swine fever virus not only has high sensitivity and strong specificity, but also has good repeatability, and the kit is suitable for being used in the detection of the African swine fever virus. The accurate detection of the African swine fever virus is realized, and a more efficient detection method is provided for the prevention, control and diagnosis of epidemic situations.

The application discloses a CSFV-PPV bivalent subunit vaccine and a preparation method thereof. The vaccine comprises a first recombinant protein encoded by a first gene, a second recombinant protein encoded by a second gene and a pharmaceutically acceptable carrier. The first gene has a sequence shown in SEQ ID NO:1 or an increased or reduced sequence thereof. The second gene has a sequence shown in SEQ ID NO:2 or an increased or reduced sequence thereof. The application takes the antigen E2 protein of CSFV (CSFV) and the VP2 protein of PPV (PPV) as double targets, expresses the recombinant SC-E2 protein with a SpyCatcher label and the recombinant ST-VP2 protein with a SpyTag label in insect cells through a recombinant baculovirus vector, realizes in-vitro covalent assembly of the double antigens, and constructs the bivalent subunit vaccine which can simultaneously prevent and control two diseases, and has the advantages of high safety, strong immunogenicity, high prevention and control efficiency and easiness in large-scale production.

The present invention provides use of magnoline in the preparation of an antiviral drug, which belongs to the technical field of antiviral drugs. The present invention demonstrates at the cellular level that magnoline exhibits an inhibitory effect on various common infectious disease viruses in domestic pigs, especially in vitro exhibits a significant inhibitory effect on the proliferation of African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), and porcine epidemic diarrhea virus (PEDV). Further disclosed in the present invention are an antiviral composition consisting of the active ingredient magnoline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and / or excipient, and use of the composition in the preparation of a viral infection inhibitor and / or in the preparation of a pharmaceutical formulation for preventing and / or treating viral infectious diseases, thereby providing a basis for the development of new broad-spectrum antiviral drugs.

A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and / or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and / or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

The present invention relates to a mammalian 293i cell expression, monoclonal antibody preparation, epitope identification and application targeting ASFV K205R encoded protein. By constructing a eukaryotic expression vector pCDNA3.4-K205R-strep, transiently transfecting 293i cells to express recombinant pK205R protein, immunizing Balb / c mice after purification, and fusing mouse spleen cells with myeloma SP2 / 0 cells after four immunizations to prepare hybridoma cells, then subcloning using an indirect ELISA method to obtain a monoclonal antibody against the pK205R protein, and determining the antigenic epitope corresponding to the antibody. 2 VEPREQFFQDLLSAV 16 .

The invention belongs to the technical field of animal epidemic disease control, and particularly relates to a competitive ELISA detection method for ASFV detection. The method comprises the following steps: sealing a spare plate, adding a sample, detecting, developing, judging and the like. Based on the two prepared novel probes (based on a streptavidin magnetic bead modified African swine fever virus K205R protein probe and a specific monoclonal antibody-HRP fusion probe), a competitive ELISA detection method for detecting ASFV is constructed, and the ASFV can be well detected in combination with optimization of related experimental detection conditions. Preliminary experiment results show that the ELISA detection method provided by the invention has good reproducibility and specificity, does not need to use a commercial secondary antibody and an excessive washing process, can greatly simplify operation steps and detection time, and has good practical value and technical significance for rapid and convenient determination of ASFV and early prevention and control of ASF.

The present invention relates to an in vitro diagnostic method for distinguishing an animal infected with African swine fever virus (ASFV) from an animal that has been vaccinated against ASFV using an immunogenic composition comprising an attenuated ASFV in which the EP153R gene and the EP402R gene have been inactivated and in which a region of the ASFV genome comprising the EP402R and EP153R genes is replaced with a heterologous gene.

This invention discloses a monoclonal antibody BY013 that binds to the African swine fever virus (ASFV) P30 protein and its applications. This invention provides an IgG antibody composed of a light chain and a heavy chain; CDR1, CDR2, and CDR3 in the variable region of the heavy chain are as shown in positions 47-54, 72-79, and 118-130 of SEQ ID NO: 1, respectively; CDR1, CDR2, and CDR3 in the variable region of the light chain are as shown in positions 49-60, 78-80, and 117-124 of SEQ ID NO: 3, respectively. This invention also protects the application of any of the above-described IgG antibodies in the preparation of products; the functions of the products are: binding to the ASFV P30 protein fragment; binding to the ASFV P30 protein; and binding to ASFV. The IgG antibody provided by this invention can be used for various applications such as Western blot, immunohistochemistry, flow cytometry, and ELISA, and can serve as an important tool for ASFV detection and structural analysis of the P30 protein.

An injectable, oral or nasal spray multivalent vaccine treats or prevents infection with a coronavirus, and / or influenza, and / or respiratory syncytial virus (RSV), or other viruses such as African swine fever virus (ASFV). The multivalent vaccine comprises a hybrid pseudovirus assembled from any of the following combinations of primary proteins: coronavirus S, and / or influenza HA and / or RSV fusion protein, and / or ASFV p12 plus any of the following secondary proteins from either: coronavirus N, M, and E, and / or Influenza NA,M1,M2 and NP and / or RSV Matrix, G, and Nucleocapsid, and / or ASFV p35, p27, p14. These hybrid pseudoviruses package an alphaviral vector carrying RNA encoding multiple receptor binding domain regions of the attachment or fusion proteins of these viruses, wherein the hybrid pseudovirus and alphaviral vector are combined in an injectable, oral, or nasal spray formulation.